Image via Cloud DX
(Source: Cloud DX.)
  • Cloud DX (CDX) has announced plans to launch a non-brokered private placement for aggregate gross proceeds of up to $1,750,000
  • The company will issue up to 1,750 secured convertible debentures at a price of $1,000 per debenture
  • The debentures will bear 18 per cent interest per annum
  • Cloud DX provides a digital and virtual health care platform for patient remote monitoring and hospital-quality post-surgical care
  • Cloud DX Inc. (CDX) opened trading at C$0.155

Cloud DX (CDX) has announced plans to launch a non-brokered private placement for aggregate gross proceeds of up to $1,750,000.

The company will issue up to 1,750 secured convertible debentures at a price of $1,000 per debenture.

The debentures will mature 12 months after they’re issued and shall bear 18 per cent interest per annum. The principal amount of the debenture is convertible into common shares at a conversion price of $0.15 per share any time prior to the maturity date.

Net proceeds will be used for inventory and general working capital purposes.

The offering is expected to occur in one or more tranches, with the first tranche scheduled to close on or about June 24, 2022.

The debentures and any securities issued upon conversion will be subject to a statutory four-month hold period. The offering is subject to TSX Venture Exchange approval.

Cloud DX provides a digital and virtual health care platform for patient remote monitoring and hospital-quality post-surgical care.

Cloud DX Inc. (CDX) opened trading at C$0.155.

More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.